News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured ...
The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback